Skip to content

A prospective, single-center, single-group, open-label clinical trial exploring the feasibility of using high-intensity focused ultrasound for the treatment of lower extremity varicose veins

A prospective, single-center, single-group, open-label clinical trial exploring the feasibility of using high-intensity focused ultrasound for the treatment of lower extremity varicose veins

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122420
Enrollment
Unknown
Registered
2026-04-14
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Varicose veins of the lower extremities

Interventions

Experimental Group:Focused Ultrasound Non-Invasive Vein Occlusion System

Sponsors

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age 18~80 years old (inclusive), regardless of gender; 2.The clinical diagnosis is unilateral/bilateral varicose veins of great saphenous veins of lower limbs, and only one side is treated in this treatment; 3.Patients with CEAP grade C2-C6; 4.Doppler ultrasound confirmed that the diameter of the target vein was >=3mm and <= 15 mm; 5.Patients who voluntarily participate in the trial, understand all the risks and benefits stated in the informed consent document and sign the written informed consent form;

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women, or those planning to have a family during the study period/who are unable to secure effective contraception; 2. The ablated superficial veins were not suitable for treatment, including previous surgical treatment; Secondary varicose veins, such as venous thrombosis syndrome, Cockett syndrome, KT syndrome, arteriovenous fistula, etc. Superficial venous thrombosis and thrombophlebitis of the lower extremities; 3. Peripheral artery disease (ABI225 umol/L); 7. Coagulation dysfunction or obvious bleeding tendency (platelet count <=30X10%L); 8. Participated in other clinical trials within three months; 9. Malignant tumor, survival time <1 year; 10. There were unavoidable hypertrophic scars on the surface of the ablated segmental vessels. 11. Other circumstances considered by the investigator to be inappropriate for participation in the trial

Design outcomes

Primary

MeasureTime frame
Vascular closure of the treatment segment;

Secondary

MeasureTime frame
Time to return to work;Pain;Clinical-etiology-anatomy-pathophysiology venous classification system;Quality of life;Clinical effectiveness;Subject satisfaction evaluation;Time to return to activity;Vascular closure of the treatment segment;Venous clinical severity score;

Countries

China

Contacts

Public ContactYuefeng Zhu

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

zhuyuefeng@126.com+86 571 8600 6667

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026